www.fdanews.com/articles/72612-uk-drug-discovery-company-oxagen-completes-59-8-million-financing
UK Drug Discovery Company Oxagen Completes $59.8 Million Financing
May 23, 2005
Oxagen Ltd, a drug discovery and development company specializing in inflammation, announced Monday the successful completion of a $59.8 Million (GBP31.6 Million) Series B round led by MPM Capital. The proceeds of the funding will be used to advance Oxagen's lead programme, a novel small molecule anti-inflammatory for asthma to the clinic and to expand the company's clinical and preclinical stage portfolio.